Hepatitis B virus (HBV) serology has become extremely refined. As well as the recognised hepatitis B surface (HBs), hepatitis B core (HBc), and hepatitis B e (HBe) antigen-antibody systems, new markers have been introduced including pre-Sl, pre-S2 for the envelope and the functional X protein. 
C Trepo, F Zoulim, C Alonso, M-A Petit, C Pichoud, L Vitvitski Abstract Hepatitis B virus (HBV) serology has become extremely refined. As well as the recognised hepatitis B surface (HBs), hepatitis B core (HBc), and hepatitis B e (HBe) antigen-antibody systems, new markers have been introduced including pre-Sl, pre-S2 for the envelope and the functional X protein. New automates have been introduced allowing flexibility in the different tests according to precise needs. The monitoring of pre-SI antigen provides a relevant correlate of viral replication. The quantitative determination of HBV-DNA, pre-SI Ag, and IgM anti-HBc seem most useful for the decision to use, and the monitoring of, antiviral treatment. Second generation ELISAs detect antibodies to three sets ofhepatitis C virus (HCV) protein including the c22 core, and c33, and clOO, which correspond to the non-structural regions (NS3 and NS4, respectively). Second generation ELISAs require confirmation by supplement assays, but their biggest limitation is the delayed appearance of anti-HCV after primary infection. In addition 10% of chronic infections with liver disease still remain seronegative despite circulating HCV RNA in serum or liver, or both. Much progress still has to be made before HCV serology can reach the level of sophistication of HBV. (Gut 1993 The hitherto overlooked genetic heterogeneity of HBV, recently disclosed by molecular biology, has necessitated reconsideration of the classic serological distinctions between healthy carriers and progressive symptomatic or asymptomatic infection. Markers may be separated tentatively into two groups: those that are mainly diagnostic and those that allow assessment of prognosis and infectivity. HBsAg, anti-HBs, and anti-HBc should be used simultaneously for diagnosis. Moreover, in contrast with HIV or hepatitis C virus (HCV), it is often possible to confirm the specificity of one test within the HBV marker spectrum itself. For example, the specificity of HBsAg can be assessed by testing for anti-HBc or HBeAg/anti-HBe. This also applies to antiHBs as a marker of immune elimination of HBV. In isolated anti-HBc, polymerase chain reaction (PCR) should be used to investigate the possibility of low grade ongoing HBV infection. Western blot profiles and peptide analysis also confirm the specificity and variability of the anti-HBc response.
NEW AND POTENTIALLY USEFUL MARKERS OF HBV INFECTION
Three additional coding regions leading to expression of protein during the life cycle of the virus have been studied intensively: pre-Sl, pre-S2, and X. The polymerase gene product has received least attention. With suitable antibodies, the product of the polymerase gene can be shown in the liver of infected carrier patients. In a study of renal dialysis patients,' anti-polymerase antibodies have been reported as the earliest marker of HBV infection. Both in human and experimental hepadna virus infection in the woodchuck, anti-pol antibodies were constant in fulminant hepatitis and common in acute HBV infection as well as in chronic infection, where they correlated directly with the existence of ongoing HBV replication. Remarkably, the occurrence of anti-pol antibodies in chronic hepatitis B patients was about the same in those with HBeAg and those with anti-HBe. This is further evidence that ongoing viral replication in such patients may well persist in the presence of anti-HBe. proteins.13 Even though the prevalence of such mutants has been studied in various regions of the world, showing a high proportion of mutations in Africa, Asia, and the Mediterranean countries, the biological and clinical consequences of the phenomenon remain unclear. Several reports focused on the severity of the infection with such mutated strains, including propensity to fulminant hepatitis and rapidly progressing chronic active hepatitis. We have recently confirmed the replication capacity of this HBV mutant and successfully shown by transfection the infectivity for chimpanzees."4 Although our results suggested decreased replication ability of pre-core negative mutated HBV variants, they confirmed the ability to infect both in vivo and in vitro. Remarkably, the infection with pre-core negative mutants is associated with cytoplasmic rather than nuclear expression of HBcAg. This provides indirect evidence of the existence of HBeAg variant strains. The existence of several populations of wild type and mutated HBV strains in patients, as well as fluctuation of such populations during the natural course of the disease or following treatment, has already been reported. 15 16 Whether some HBeAg negative variants are true 'escape mutants' and a result of immune selection, or whether they derive from direct exogenous infection needs to be studied further.
It is important to emphasise that interferon acts, in part, by immunomodulation and thus may contribute to the selection of such an escape mutant. The response of chronic active hepatitis to interferon has been shown to be related indirectly to the proportion of wild type and HBeAg negative mutants. Therefore, the detection of these mutants is now necessary for the successful management of HBV infection. It is important to remember that because of a lower HBV replication capacity, HBeAg negative infection is often associated with progressive liver disease with evidence of HBV replication in the liver, even though serum HBV-DNA tests are negative. Such infections may represent 50% or more of the cases studied at one time. The management of antiHBe positive liver disease is extremely difficult with the markers currently available as HBeAg is dismissed and HBV-DNA is present in less than half of the patients at a titre detectable by conventional hybridisation techniques. We have shown that, in such cases, study of the pre-Sl/HBsAg ratio is invaluable.9 Indeed, the pre-core negative mutation does not affect the viral envelope. Given the many tests available, it is critical to select only the minimum necessary to allow assessment of the clinical situation, including HBV variants. The need for accurate processing of a large number of samples prompted us to evaluate fully automated enzyme immunoassays (IMX Abbott, Chicago, IL, USA) for the assessment of both HBsAg and IgM anti-HBc. HBV-DNA titre was also assessed quantitively using a solution hybridisation test. '9 To assess the clinical relevance of these assays, they were compared with anti-HBx, pre-S1, and pre-S2 antigen detection. Three higher in patients with high replication (>100 pg/ml). As mentioned before, monitoring of anti-HBe positive chronic active hepatitis requires the use of additional markers. Pre-S1/HBsAg ratios were found to correlate with both the replication and severity of liver disease in anti-HBe positive patients.8
The quantitative measurement of serum HBV-DNA, IgM anti-HBc, and pre-S antigen titres is needed to discover if a patient is suffering from chronic liver disease with replicating virus and may therefore be infectious, especially in anti-HBe-positive chronic HBsAg carriers. It is important that an excellent correlation has been found between the detection of pre-Sl protein by radioimmunoassay (RIA) and HBV-DNA by PCR in HBsAg carriers.2' PCR in itself, however, is not yet readily quantifiable, even though it can detect up to five genomes in a single specimen. Most HBsAg carriers with a healthy liver will be positive on PCR, as shown in Table II . Until the cut off point for pathological significance has been determined, PCR will remain an investigative tool for research and one that must be supplemented with other assays for routine use.
REDEFINITION OF SEROLOGICAL PROFILES
It is important to integrate the relevant new markers of clinical heterogeneity of hepatitis B into the routine management of patients and to distinguish between the profiles listed below.
Primary infection
Once exposure to HBV has been shown and infection proved, it is necessary to distinguish a recent infection from an exacerbation occurring in a chronic carrier. This can be done by IgM anti-HBc titre. The increased sensitivity of this test, which allowed the introduction of a cut off value to distinguish accurately between chronic and acute infections, has redefined its significance. To date, we have assumed that all primary infection was of the wild type but, in future, we should consider whether pre-core negative mutant or mixed infections are present.
Prolonged hepatitis B Prolonged hepatitis B is defined as the persistence of abnormal serum ALT activities for more than six weeks but less than six months. The condition has to be monitored carefully and treated adequately. Evidence indicates that, whenever HBeAg and HBV-DNA persist, the chances of spontaneous recovery are almost non-existent. In but only in cases of immunodeficiency after HIV infection or immunosuppressive treatment. In cases of infection with mutated HBe(-) variant, many flare ups are seen and are part of the natural history of the infection. The term 'reactivation' should not be used loosely for every exacerbation in cases such as these.
CONCLUSIONS
We have carried out extensive analysis of the existing HBV markers, which have been improved by quantitative determination methods, to assess accurately HBV replication and to monitor its fluctuation in chronic HBV infection with both wild type or HBeAg negative variants before, during, and after antiviral treatment. The results indicate that, in addition to HBsAg, the most critical variants are pre-S 1 antigen and HBV-DNA. In general, the quantitative determination of HBV-DNA, pre-S 1 antigen, and IgM anti-HBc seems most useful for the decision to treat, and the monitoring of, antiviral treatment. This is especially true for anti-HBe positive carriers with liver disease, as HBV-DNA values are often too low to be readily detectable.
Persistence of pre-S 1 antigen and IgM antiHBc, or both confirm ongoing HBV replication, as shown by PCR, and rule out the true healthy carrier state. Therefore, there is a much smaller proportion of cases than previously thought that fall into this category. Strict criteria should be maintained, however, to identify a much larger proportion of patients with minimal liver disease who should be monitored to recognise early reactivation or emergence of mutants. Such cases could be treated more effectively if treatment was started earlier.
Hepatitis C The real breakthrough in terms of sensitivity was achieved when it became possible to add a second adjacent non-structural protein (NS3 or c33) and a structural protein from the viral capsid or core (c22) to the c 100-3 NS4 protein. This set of three proteins was selected carefully after extensive testing, and two major diagnostic companies (Ortho and Abbott) are presently distributing second generation ELISAs based on the association between the three. Other manufacturers which use distinct recombinant proteins (Pasteur Diagnostic and Wellcome) or combined synthetic peptides (UBI Organon) are accessing the market, but they have yet to offer strong competition with the market leaders. Results from second generation assays are only beginning to be reported in studies and most references still document first generation assays. The principle of anti-hepatitis C virus (HCV) ELISA, first and second generation, is based on a 'sandwich' antiglobulin assay in which recombinant proteins or synthetic peptides fixed on a solid phase bind the antibodies present in the serum. Those antibodies are shown by anti-human IgG. As for HIV tests, this type of assay is associated with specificity S23 problems; any antibody to protein which may be fixed together with HCV specific protein will also react and will need to be assessed further by supplementary testing. Therefore, HCV screening must include initial assays with maximum sensitivity followed by confirmatory assays providing the necessary specificity. Sensitivity and specificity in HCV infection are still limited, as will become apparent.
The increased proficiency associated with the use of second generation assays is important, although variable, and depends on the clinical setting. For example, in the screening of blood donors in France, the number of positive samples in low prevalence areas almost doubled when second generation tests were used. In high risk groups, such as drug addicts, an increase in true positives from 5 to 40% was seen with second generation assays. Among patients with chronic non-A, non-B (NANB) hepatitis, the increase of 5 to 15% brought the final anti-HCV reactivity rate to over 85%. Among patients with acute sporadic NANB hepatitis, the improved rate of detection was about 20%. In prospective studies after transfusion, anti-HCV was detected 30-90 days earlier with second generation assays, and it is now clear that all cases seroconverted within five months after transfusion. Despite these benefits, between 20 and 40% of cases of presumed acute hepatitis C remain anti-HCV negative on tests carried out at the start of symptoms or at peak ALT activity. The higher reactivity rate associated with sporadic acute hepatitis may partly be a result of misinterpretation of established chronic infection. In contrast with the delayed appearance of anti-HCV, detection of HCV-RNA on PCR is an early event, occurring as soon as five to 10 days after transfusion. In addition, 1 0% of patients with chronic hepatitis C may be seronegative for anti-HCV; in such cases, only HCV-RNA can be shown by PCR. The prevalence of anti-HCV negativity is increased in cases of immunodeficiency linked to either HIV infection or transplantation. These Thus, because of their limited specificity, each anti-HCV assay must be followed by a complementary 'confirmation' test. Several such complementary assays are now available and are described below. To date, the immunoblot type tests have been used most commonly, in which the structural protein c22 and non-structural proteins c33 and c100 are coated as separate bands on nitrocellulose strips (RIBA, Ortho; Raritan, New Jersey, USA) or disks (MATRIX, Abbott, Chicago, IL, USA). These tests have excellent specificity but lack sensitivity. Among blood donors, they yield too many indeterminate results; 30% detect only one of the proteins (c22 or c33 antibodies) and yet two proteins are required for a true positive result. The supplemental 'two beads' assay (Abbott) consists of two separate beads coated with c22 (structural) and c33+c 100 (non-structural) proteins. This assay has good sensitivity and specificity, and scores positive if the sample is reactive with only one bead.
The conflicting interpretations of serological data require clarification. Some suggest that a blood donor positive for only one protein may well be truly infected with HCV, whereas others suspect a false reaction as a likely cause of this commonly seen pattern. Indeed, most blood donors with only one protein are not infectious, but this does not mean that they have not been exposed to HCV. They may retain a residual anti-c22 reactivity resulting from the sequential loss of c33 and, later, c100
antibodies, as the c22 antibody seems to be the most persistent. In liver disease patients, however, most cases of anti-c22 or anti-c33 single reactivity are hepatitis C viraemic, as indicated by PCR. Thus, it seems important to assay RIBA-2 indeterminate samples by PCR to confirm HCV infection.
PCR testing should also be performed in autoimmune groups, as chronic active autoimmune hepatitis is commonly associated with false positive reactions. Two types of autoimmune hepatitis must be distinguished: type 1, associated with antismooth muscle antibodies of the anti-actin type, and in which anti-HCV is usually non-specific, non-neutralisable, and not confirmed by immunoblot; type 2, characterised by the presence of anti-liver kidney microsomal 1 antibodies, with confirmation of anti-HCV by immunoblot in more than 75% of cases. 28 As treatment of HCV infection with interferon exacerbates the autoimmunity reactions, the search for HCV-RNA by PCR in the serum, lymphocytes, or liver seems imperative in autoimmune diseases associated with anti-HCV poSitiVity.32 33 The search for HCV-RNA also seems necessary in acute or chronic anti-HCV seronegative hepatitis. Immunostaining techniques capable of showing HCV proteins in the liver should be developed further.
It should be emphasised that the 'confirmatory tests' cannot be expected to reflect the actual viraemia, nor can they be used after antiviral treatments, as they predict neither the probability of response nor relapse. Therefore, it is necessary to develop new tests with additional proteins distinct from those used in the ELISA, to meet the prerequisites of a true confirmatory assay.
Conclusions
HCV serology is evolving rapidly, but we still need to be aware of both false positive and false negative anti-HCV results. All positive screening tests should be confirmed by supplemental assays such as RIBA-2, MATRIX, or double-bead type assays. Indeterminate results should be confirmed by investigation of HCV-RNA using PCR, particularly in patients with anti-HCV positive autoimmune hepatitis.
Immunostaining of the liver and anti-HCV IgM are showing great promise, but we still need serological markers to distinguish between immune patients who have cleared HCV, so-called 'healthy carriers', and infectious patients with replicating virus and progressive disease. Thus, HCV serology requires considerable refinement before reaching the level of sophistication achieved for HBV. 
